TRCT
TEVA icon

Tower Research Capital (TRC)’s Teva Pharmaceuticals TEVA Stock Holding History

Tower Research Capital (TRC)’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.2K Buy
+627
New +$20.9K ﹤0.01% 3492
2026
Q1 		– Sell
-102
Closed -$3.18K – 5556
2025
Q4 		$3.18K Sell
102
-6,090
-98% -$150K ﹤0.01% 4412
2025
Q3 		$125K Buy
6,192
+5,462
+748% +$95.9K ﹤0.01% 1824
2025
Q2 		$12.2K Sell
730
-1,801
-71% -$29.1K ﹤0.01% 3890
2025
Q1 		$37.7K Buy
2,531
+1,792
+242% +$32K ﹤0.01% 2439
2024
Q4 		$16.3K Sell
739
-28,880
-98% -$525K ﹤0.01% 3365
2024
Q3 		$534K Buy
29,619
+26,520
+856% +$464K 0.01% 824
2024
Q2 		$50.4K Buy
3,099
+1,936
+166% +$29.8K ﹤0.01% 3096
2024
Q1 		$16.4K Buy
1,163
+808
+228% +$10.2K ﹤0.01% 3182
2023
Q4 		$3.71K Sell
355
-3,432
-91% -$32K ﹤0.01% 5050
2023
Q3 		$38.6K Buy
3,787
+3,580
+1,729% +$33.3K ﹤0.01% 2782
2023
Q2 		$1.56K Sell
207
-2,375
-92% -$19.3K ﹤0.01% 5357
2023
Q1 		$23K Buy
2,582
+454
+21% +$4.49K ﹤0.01% 3299
2022
Q4 		$19K Sell
2,128
-1,345
-39% -$11.7K ﹤0.01% 3189
2022
Q3 		$28K Sell
3,473
-2,592
-43% -$22.9K ﹤0.01% 3668
2022
Q2 		$46K Sell
6,065
-14,206
-70% -$124K ﹤0.01% 2974
2022
Q1 		$190K Buy
+20,271
New +$169K ﹤0.01% 1767
2021
Q4 		– Sell
-6,273
Closed -$61K – 6564
2021
Q3 		$61K Sell
6,273
-21,790
-78% -$204K ﹤0.01% 2800
2021
Q2 		$278K Buy
28,063
+15,183
+118% +$161K 0.01% 1670
2021
Q1 		$148K Sell
12,880
-31,693
-71% -$363K ﹤0.01% 2264
2020
Q4 		$430K Buy
44,573
+16,043
+56% +$154K 0.01% 1104
2020
Q3 		$257K Buy
28,530
+27,641
+3,109% +$292K ﹤0.01% 2330
2020
Q2 		$11K Sell
889
-20,727
-96% -$234K ﹤0.01% 3976
2020
Q1 		$194K Buy
21,616
+4,034
+23% +$41.3K 0.01% 766
2019
Q4 		$172K Buy
17,582
+17,229
+4,881% +$154K 0.01% 652
2019
Q3 		$2K Buy
+353
New +$2.71K ﹤0.01% 3744
2019
Q2 		– Sell
-7,955
Closed -$125K – 4274
2019
Q1 		$125K Sell
7,955
-30,044
-79% -$530K 0.01% 1336
2018
Q4 		$586K Buy
37,999
+34,102
+875% +$699K 0.04% 379
2018
Q3 		$84K Buy
3,897
+3,087
+381% +$71.7K 0.01% 1456
2018
Q2 		$20K Sell
810
-810
-50% -$16.5K ﹤0.01% 2440
2018
Q1 		$28K Buy
1,620
+1,428
+744% +$27.9K ﹤0.01% 2001
2017
Q4 		$4K Buy
+192
New +$2.89K ﹤0.01% 3013
2017
Q3 		– Sell
-100
Closed -$3K – 4139
2017
Q2 		$3K Sell
100
-23
-19% -$712 ﹤0.01% 2244
2017
Q1 		$4K Sell
123
-2,158
-95% -$73.6K ﹤0.01% 2344
2016
Q4 		$83K Sell
2,281
-5,216
-70% -$208K 0.01% 1070
2016
Q3 		$345K Buy
7,497
+6,843
+1,046% +$357K 0.03% 262
2016
Q2 		$33K Buy
+654
New +$34.8K ﹤0.01% 1862
2016
Q1 		– Sell
-608
Closed -$40K – 4919
2015
Q4 		$40K Buy
+608
New +$37.6K 0.01% 696
2014
Q3 		– Sell
-800
Closed -$42K – 4881
2014
Q2 		$42K Buy
800
+634
+382% +$32.4K 0.01% 1387
2014
Q1 		$9K Sell
166
-12,421
-99% -$574K ﹤0.01% 2731
2013
Q4 		$504K Buy
12,587
+12,169
+2,911% +$479K 0.08% 182
2013
Q3 		$16K Buy
418
+264
+171% +$10.3K ﹤0.01% 2877
2013
Q2 		$6K Buy
+154
New +$6K ﹤0.01% 2825

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Tower Research Capital (TRC)'s TEVA Position: Q2 2026 in Review

Tower Research Capital (TRC) opened a new position in Teva Pharmaceuticals (TEVA) in Q2 2026: 627 shares worth $21.2K. The stake represents ﹤0.01% of the portfolio and ranks #3492 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in TEVA as recently as Q4 2025.

Tower Research Capital (TRC) first reported a position in TEVA in Q2 2013 and has held it in 43 quarters since. The position peaked at $586K in Q4 2018. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Tower Research Capital (TRC) held 627 shares of Teva Pharmaceuticals worth $21.2K as of Q2 2026.
  • Teva Pharmaceuticals was a new Tower Research Capital (TRC) position in Q2 2026.
  • Teva Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3492 holding.
  • Tower Research Capital (TRC) first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 43 quarters since.
  • Tower Research Capital (TRC)'s Teva Pharmaceuticals position peaked at $586K in Q4 2018.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.